Fliegner L, Spiegel P
Hautarzt. 1992 Sep;43(9):554-60.
A case of fully reversible tubular toxicity with consecutive metabolic osteopathy following systemic fumaric acid therapy is reported. This secondary effect of oral fumaric acid therapy obviously occurs very rarely, never having been described before. A 46-year-old female patient with a long history of recurrent palmoplantar psoriasis underwent oral treatment with fumaric acid and its esters in accordance with the Schäfer method, preceding attempts at curative treatment with conventional antipsoriatic agents having proved unsatisfactory. Two months later, the patient started to experience arthralgia, back pain in the early hours of the morning and myalgia with increasing frequency, progressing to disablement in moving and walking and, finally, to total immobility. Not until 9 months later was the reason for these severe disabilities found: they stemmed from hypophosphataemic osteomalacia as a result of a complex disturbance of the renal tubular system. The clinical symptoms and the results of laboratory chemistry tests returned to normal as soon as fumaric acid medication was discontinued. Two attempts at reexposure confirmed the causal relationship. Oral fumaric acid medication should never be administered without clinical and chemical controls.
报告了一例系统性富马酸治疗后出现完全可逆性肾小管毒性并伴有连续性代谢性骨病的病例。口服富马酸治疗的这种继发效应显然极为罕见,此前从未有过描述。一名有复发性掌跖银屑病病史的46岁女性患者,在使用传统抗银屑病药物进行治疗效果不佳后,按照舍费尔方法接受了富马酸及其酯类的口服治疗。两个月后,患者开始频繁出现关节痛、凌晨背痛和肌痛,逐渐发展到行动和行走受限,最终完全无法活动。直到9个月后才找到这些严重残疾的原因:它们源于肾小管系统复杂紊乱导致的低磷性骨软化症。停用富马酸药物后,临床症状和实验室化学检查结果立即恢复正常。两次重新用药尝试证实了因果关系。在没有临床和化学监测的情况下,绝不应给予口服富马酸药物。